Form 4: Blueprint Medicines CFO Michael Landsittel Executes Stock Option and Sells Shares Under 10b5-1 Plan

Michael Landsittel, CFO of Blueprint Medicines, exercised stock options and sold 10,000 shares of common stock at $105 per share on May 2, 2024, under a pre-arranged trading plan.

Summary

• On May 2, 2024, Michael Landsittel, the Chief Financial Officer of Blueprint Medicines Corp, executed a transaction involving the company's stock.
• Landsittel exercised a stock option to acquire 10,000 shares at a price of $36.05 per share.
• Simultaneously, Landsittel sold 10,000 shares of common stock at $105 per share.
• These transactions were executed under a pre-arranged trading plan adopted on December 6, 2023, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following these transactions, Landsittel beneficially owns 47,286 shares of Blueprint Medicines Corp.
• Landsittel has granted limited power of attorney to Tracey McCain, Melissa Masse, Ariel Hurley, and himself to handle SEC filings related to company stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock transactions by a company executive. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry. The use of 10b5-1 plans allows insiders to sell shares while avoiding accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The exercise and sale of shares by executives are typical events, but the timing and volume are scrutinized by investors.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.
• The use of 10b5-1 plans is a standard practice among public companies to provide a legal framework for insider trading.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates